Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study

BACKGROUND: Indacaterol is a novel, once-daily (o.d.) inhaled, long-acting β(2)-agonist in development for chronic obstructive pulmonary disease (COPD). This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol to that of placebo in patients with moderate-to-sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldman, Gregory, Siler, Thomas, Prasad, Niyati, Jack, Damon, Piggott, Simon, Owen, Roger, Higgins, Mark, Kramer, Benjamin
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848004/
https://www.ncbi.nlm.nih.gov/pubmed/20211002
http://dx.doi.org/10.1186/1471-2466-10-11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848004/
https://www.ncbi.nlm.nih.gov/pubmed/20211002
http://dx.doi.org/10.1186/1471-2466-10-11

Ejemplares similares